東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Positron Emission Tomography (PET) o...

Kwon, Yongkyu.

FindBook

Google Book

Amazon

博客來

Positron Emission Tomography (PET) of Breast Cancer Heterogeneous for HER2 and EGFR Using Bispecific Radioimmunoconjugates.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Positron Emission Tomography (PET) of Breast Cancer Heterogeneous for HER2 and EGFR Using Bispecific Radioimmunoconjugates./
作者:	Kwon, Yongkyu.
出版者:	Ann Arbor : ProQuest Dissertations & Theses, : 2019,
面頁冊數:	175 p.
附註:	Source: Dissertations Abstracts International, Volume: 81-06, Section: B.
Contained By:	Dissertations Abstracts International81-06B.
標題:	Pharmaceutical sciences. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=22583411
ISBN:	9781392791301

Positron Emission Tomography (PET) of Breast Cancer Heterogeneous for HER2 and EGFR Using Bispecific Radioimmunoconjugates.
Kwon, Yongkyu.

Positron Emission Tomography (PET) of Breast Cancer Heterogeneous for HER2 and EGFR Using Bispecific Radioimmunoconjugates. - Ann Arbor : ProQuest Dissertations & Theses, 2019 - 175 p.

Source: Dissertations Abstracts International, Volume: 81-06, Section: B.

Thesis (Ph.D.)--University of Toronto (Canada), 2019.

This item must not be sold to any third party vendors.

The human epidermal growth factor receptor-2 (HER2) is overexpressed in 15-20% of breast cancer (BC) and is the target for immunotherapy with trastuzumab, pertuzumab, and trastuzumab-emtansine (T-DM1). Despite improvements in survival, resistance to HER2-targeted therapies remains a major problem. One resistance mechanism is loss of HER2 and increased EGFR. Additionally, intratumoral HER2 heterogeneity is correlated with a poor response to trastuzumab. The hypothesis was that novel bispecific radioimmunoconjugates (bsRICs) are capable of permit molecular imaging of both EGFR and HER2 receptors simultaneously with positron emission tomography (PET) and deliver more radioactivity to the tumor especially in the presence of receptor heterogeneity.BsRICs was developed by chemically linking trastuzumab Fab (anti-HER2) to human EGF through a 24-mer polyethylene glycol (PEG24) spacer, and radiolabeled with 64Cu. 64Cu-NOTA-Fab-PEG24-EGF demonstrated the ability to specifically bind to EGFR or HER2 both in vitro and in vivo, and exhibited prolonged blood circulation than monospecific agents in mice. PET imaging was performed on NOD-SCID mice bearing tumor xenografts expressing EGFR, HER2, or both receptors. Tumors were clearly visualized by microPET/CT imaging, and biodistribution studies showed significantly better tumor uptake for bsRICs in tumor xenograft expressing both receptors. Human cancer xenograft mouse models with heterogeneous levels of HER2 and EGFR was established by subcutaneous inoculation of mixtures of SK-OV-3 cells and MDA-MB-468 cells. These BC xenografts were more clearly visualized by microPET/CT, and bsRICs exhibited higher tumor uptake and lower degree of heterogeneous uptake than monospecific agents.These results suggest that bsRICs may be useful for imaging of HER2-positive heterogeneous BC consisting of EGFR-positive subpopulations. Thus, bsRICs will be able to address the challenge of HER2 intratumoral heterogeneity in BC.

ISBN: 9781392791301Subjects--Topical Terms:

3173021
Pharmaceutical sciences.
Subjects--Index Terms:

Bispecific Radioimmunoconjugate

Positron Emission Tomography (PET) of Breast Cancer Heterogeneous for HER2 and EGFR Using Bispecific Radioimmunoconjugates.
LDR:03227nmm a2200361 4500 001 2272676
005 20201105110153.5
008 220629s2019 ||||||||||||||||| ||eng d
020 $a 9781392791301
035 $a (MiAaPQ)AAI22583411
035 $a AAI22583411
040 $a MiAaPQ $c MiAaPQ
100 1 $a Kwon, Yongkyu. $3 3550105
245 1 0 $a Positron Emission Tomography (PET) of Breast Cancer Heterogeneous for HER2 and EGFR Using Bispecific Radioimmunoconjugates.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2019
300 $a 175 p.
500 $a Source: Dissertations Abstracts International, Volume: 81-06, Section: B.
500 $a Advisor: Reilly, Raymond M.
502 $a Thesis (Ph.D.)--University of Toronto (Canada), 2019.
506 $a This item must not be sold to any third party vendors.
520 $a The human epidermal growth factor receptor-2 (HER2) is overexpressed in 15-20% of breast cancer (BC) and is the target for immunotherapy with trastuzumab, pertuzumab, and trastuzumab-emtansine (T-DM1). Despite improvements in survival, resistance to HER2-targeted therapies remains a major problem. One resistance mechanism is loss of HER2 and increased EGFR. Additionally, intratumoral HER2 heterogeneity is correlated with a poor response to trastuzumab. The hypothesis was that novel bispecific radioimmunoconjugates (bsRICs) are capable of permit molecular imaging of both EGFR and HER2 receptors simultaneously with positron emission tomography (PET) and deliver more radioactivity to the tumor especially in the presence of receptor heterogeneity.BsRICs was developed by chemically linking trastuzumab Fab (anti-HER2) to human EGF through a 24-mer polyethylene glycol (PEG24) spacer, and radiolabeled with 64Cu. 64Cu-NOTA-Fab-PEG24-EGF demonstrated the ability to specifically bind to EGFR or HER2 both in vitro and in vivo, and exhibited prolonged blood circulation than monospecific agents in mice. PET imaging was performed on NOD-SCID mice bearing tumor xenografts expressing EGFR, HER2, or both receptors. Tumors were clearly visualized by microPET/CT imaging, and biodistribution studies showed significantly better tumor uptake for bsRICs in tumor xenograft expressing both receptors. Human cancer xenograft mouse models with heterogeneous levels of HER2 and EGFR was established by subcutaneous inoculation of mixtures of SK-OV-3 cells and MDA-MB-468 cells. These BC xenografts were more clearly visualized by microPET/CT, and bsRICs exhibited higher tumor uptake and lower degree of heterogeneous uptake than monospecific agents.These results suggest that bsRICs may be useful for imaging of HER2-positive heterogeneous BC consisting of EGFR-positive subpopulations. Thus, bsRICs will be able to address the challenge of HER2 intratumoral heterogeneity in BC.
590 $a School code: 0779.
650 4 $a Pharmaceutical sciences. $3 3173021
653 $a Bispecific Radioimmunoconjugate
653 $a Breast Cancer
653 $a Copper-64
653 $a Human Epidermal Growth Factor Receptor 2
653 $a Molecular Imaging
653 $a Positron Emission Tomography
690 $a 0572
710 2 $a University of Toronto (Canada). $b Pharmaceutical Sciences. $3 3170825
773 0 $t Dissertations Abstracts International $g 81-06B.
790 $a 0779
791 $a Ph.D.
792 $a 2019
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=22583411